---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-272363"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:07:38.215942+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Surrozen Q3 net loss $71.6M, appoints new CFO

## Summary
- Net loss $71.6M ($8.36/diluted share) vs $1.4M ($0.44) YoY; driven by $40.7M non-cash tranche liability loss and $20.9M other expense.
- Revenue fell to $1.0M (all from related party) from $10.0M in Q3 2024, due to absence of Boehringer Ingelheim milestone payment.
- Cash $81.3M at Sep 30, 2025 (down from $90.4M at Jun 30); R&D $7.8M vs $5.2M, G&A $4.1M vs $3.6M YoY.
- Andrew Maleki appointed CFO effective Nov 12, 2025; Charles Williams continues as COO and Secretary.
- Company on track to submit IND for SZN-8141 in 2026; ophthalmology pipeline remains focus.

## SEC filing metadata
- accession: 0001193125-25-272363
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000119312525272363/0001193125-25-272363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000119312525272363/srzn-20251107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-272363
- JSON: https://secwatch.observer/filing/0001193125-25-272363.json
- Plain text: https://secwatch.observer/filing/0001193125-25-272363.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.